News

Overall, the study authors concluded that the immunogenicity of QIV and TIV was similar for common influenza ingredients for children aged 6 to 35 months.

Biopharmaceutical company, Barinthus Biotherapeutics, studied its investigational immunization candidate, VTP-300, together with Arbutus Biopharma’s hepatitis B (HBV) therapeutic, imdusiran.

In this week's news, we covered the HCV elimination program, recent food recalls, live biotherapeutic products for recurrent C diff, and the availability of a monoclonal antibody for RSV prevention in infants.

With the holiday upon us, here are some considerations for dinner prep as well as some recent FDA food recalls.

Hepatitis B virus vaccination shown to to significantly improve survival rates for patients with chronic hepatitis C, nonalcoholic liver disease, and liver cirrhosis.

The FDA says the recall being performed by Wilcox Ice Cream is doing this out of concern for listeria contamination in the products.

Tatyana Kushner, MD, MSCE, offers her insights on the Biden administration's hepatitis C elimination plan.

A study demonstrates the microbiome changes and how restoration of the gut flora is warranted when patients are dealing with recurrent bouts of the health care-associated infection.

Madhumita Premkumar, MD, discusses a nationwide, cost-efficient eradication strategy she believes could benefit Americans' efforts to curb HCV.

The FDA and CDC announced the availability of additional doses of nirsevimab-alip for infants at high-risk of infection.

Shionogi’s therapy, ensitrelvir, was found to reduce and prevent these issues.

This week we covered antibiotic de-escalation, the approved fecal microbiota options for prevention of recurrent Clostridioides difficile, the CDC's recommendations for HCV testing in the pediatric populations, and examining pragmatic approaches to skin and soft tissue Infections.

At the American Association for the Study of Liver Diseases (AASLD) meeting held last week, Barinthus Biotherapeutics announced the presentation of data from its hepatitis B clinical trials.

The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.

Seres Therapeutics reported its financials recently including the performance of it therapy, Vowst, as well as updates on its business and one of its investigational therapies.

The investigational agent, afabicin, was developed by private company, Debiopharm, and a clinician offers some insights on the therapy in these 2 therapeutic areas.

Empirical antibiotic therapy in diabetic foot ulcer infections increases hospitalization and prolonged symptoms in patients being treated for lower limb cellulitis are common. Two recent papers examine the need for effective communication, the importance of objective findings in cellulitis management, and the benefits of culture-based antibiotic therapy in diabetic foot ulcer cases.

We’ve compiled a list of key food safety tips that you need to know in order to have a safe, bacteria-free holiday.

With the FDA approval of 2 of these products, which are indicated for recurrent Clostridioides difficile infection (CDI), a study reviewed which types of clinicians are prescribing them and the protocols in using them.

CDC recommends HCV testing in these populations as a critical step to achieving national priority of eliminating HCV.

Although the current reimbursement model makes it difficult for pharmaceutical companies to recoup their investments, a subscription model like the prospective congressional bill, the Pasteur Act, may help change that paradigm. In addition, there are international measures being carried out that may bring about changes.

The companies announced a licensing agreement on cefepime-taniborbactam.

ACON Laboratories’ Flowflex COVID-19 Antigen Home Test completed the premarket review pathway and is the first test indicated for use in children under 18.

This week read about virus testing, the dosing of one of the COVID-19 vaccines in the pediatric population, HAI grades in hospitals, and live biotherapeutic products in preventing recurrent CDI in older adults with comorbidities.

Valneva’s VLA1553 (Ixchiq) vaccine was shown to met its preliminary endpoint, with 98.9% of participants reaching protective levels of chikungunya virus neutralizing antibodies 1 month after vaccination.

Use of antiviral therapy was linked to a decreased risk of multiple cardiovascular outcomes and mortality compared to patients not using antiviral therapy.

With the addition of 2 new live biotherapeutic products, a clinician reviews the application, storage and administration techniques for them.

New data showed an approximate 60% success rate of recurrent C difficile prevention in adults with comorbid conditions including CKD and cardiac disease.